Myriad chooses Diaz as new CEO; plus changes at Novocure, Werewolf, Jasper, Avacta, Tarsus and more

Former Kindred Healthcare CEO Paul Diaz has become president and CEO of  Myriad Genetics Inc. (NASDAQ:MYGN). He replaces Mark Capone, who left the molecular diagnostics company in February after the company’s fiscal 2Q earnings disappointed.

Mike Ambrogi stepped down as COO of Novocure Ltd. (NASDAQ:NVCR) and will become a senior technology fellow, one of several management changes the cancer company announced Thursday. Ambrogi is succeeded by CFO Wilco Groenhuysen, who in turn will be succeeded in his role by Ashley Cordova. She was SVP of finance and investor relations. Novocure also promoted Frank Leonard to the newly created role of chief development officer from SVP, corporate strategy and health policy...